Pestalozzi advises Aspreva on the USD 915 million takeover by Galenica
In October 2007, the Galenica Group entered into an agreement to acquire the Canadian pharmaceutical company Aspreva Pharmaceuticals Corporation. The purchase price offered was USD 26 per share. At an extraordinary general meeting in 17 December 2007, the Aspreva shareholders voted with a majority of 99% to accept Galenica's offer. It is also planned to delist Aspreva, whose shares are currently traded on the NASDAQ Global Select Market and on the Toronto. Pestalozzi advised Aspreva on the Swiss law aspects of the transaction.